We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Technology for Making Nanoparticles

By Biotechdaily staff writers
Posted on 11 Jul 2005
A new technology breakthrough can create the world's tiniest manufactured particles for delivering drugs and biologic materials into the human body.

The technology provides control over shape, size, and composition of material when manufacturing nanoparticles. More...
This innovative new process has widespread applications, including drug formulation, drug delivery, medical imaging and disease detection, and nonmedical applications such as sensors, ink-jet printing, and microelectronics.

Called PRINT (particle replication in nonwetting templates), the technology enables the fabrication of custom-sized, monodispersed, and shape-specific particles of virtually any material and encapsulating nearly any active cargo. The latter includes delicate substances, biologic agents, and small molecules, which can be delivered through a full range of injectable, pulmonary, topical, and oral methods.

"This technique allows for development of a particle foundry, similar to continuous manufacturing techniques in the microelectronics industry, but for fabricating delicate particles for use in nanomedicines and other emerging technologies,” said Dr. W. Lowry Caudill, executive chairman of Liquidia Technologies (Research Triangle Park, NC, USA).

"Nanoparticle fabrication, until now, has focused on inorganic materials such as metals that involve harsh manufacturing methods and often are not useful for medical applications,” explained Joseph M. DeSimone, co-founder of Liquidia Technologies and professor of chemistry and chemical engineering at the University of North Carolina at Chapel Hill (USA). "This technology allows for the first time fabrication of particles for vaccines and therapies that are nontoxic for patients since the particles themselves are made from well-known bioabsorbable organic materials. Impressions are made with what we call liquid Teflon, and the resulting molds look something like ice cube trays with tiny cavities in them. After that, we mold the carrier and fragile functional materials into whatever particles we want.”






Related Links:
Liquidia Technologies

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
HPV Test
Allplex HPV28 Detection
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.